ARTIFICIAL INTELLIGENCE AND CANCER DIAGNOSIS IN LOW AND LOWER-MIDDLE-INCOME COUNTRIES: A MODERN APPROACH AND SCIENTIFIC ANALYSIS

Malignant tumors represent one of the most pervasive and formidable challenges to global public health in the modern era. Unlike benign tumors, which are often localized and manageable, malignant neoplasms possess an aggressive capacity for metastasis, posing a direct and existential threat to patients life. Historically, the high mortality rates associated with these diseases are not merely a product of biological virulence, but are significantly driven by the systemic failure of late-stage diagnosis. This crisis is particularly acute in low and lower-middle-income countries (LLMICs), where fragile healthcare infrastructures and limited access to specialized oncological screening often struggle to keep pace with the rapidly rising incidence of the disease. The gravity of this public health emergency is starkly illustrated by recent epidemiological data from Central Asia. In Uzbekistan alone, the year 2022 saw 35,900 new cancer diagnoses and 22,071 recorded deaths, highlighting a devastating mortality-to-incidence ratio. Such figures underscore a critical and immediate urgency for the integration of innovative, scalable diagnostic solutions that can bypass traditional infrastructural bottlenecks. This paper investigates the transformative potential of Artificial Intelligence (AI) as a pivotal tool in bridging the diagnostic gap in resource-constrained environments. By leveraging advanced machine learning algorithms, deep learning for medical imaging, and predictive modeling, AI offers a pathway to democratize high-level oncological expertise. The study explores how these technologies can enhance the precision of early detection specifically in prevalent cases such as breast, stomach, and colorectal cancers thereby reducing human diagnostic error and significantly improving patient survival outcomes. Ultimately, the integration of AI is presented not merely as a technological luxury, but as a fundamental necessity for modernizing cancer care in developing nations.